Urocortin
A native 40-amino-acid corticotropin-releasing factor family peptide that activates both CRF receptor subtypes, studied as a cardiovascular and stress hormone; its relative urocortin 2 reached phase 2 heart-failure trials, but no urocortin product is approved anywhere.
Also referenced as: Urocortin 1, Urocortin I, Ucn1, Ucn-1
Also appears in: Hormone
Public product evidence No certificate records are bound to a tracked Urocortin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Urocortin product pages. Other certificates naming this compound may still exist — search the wider certificate database.This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Cardiovascular. Also surfaces under Hormone for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Urocortin 1, Urocortin I, Ucn1, Ucn-1
No FDA label signal · 14 trials · 1000 PubMed results
Current evidence for Urocortin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Urocortin has 6 name-matched clinical trials (highest phase: no phased trial) and 1000 PubMed-indexed publications and is not FDA-approved. Note: 2 retracted publications in the literature.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Urocortin?
Urocortin is a native 40-amino-acid peptide hormone of the corticotropin-releasing factor (CRF) family, the same family as the hypothalamic hormone CRF, whose synthetic form is corticorelin. It was discovered at the Salk Institute in 1995 when a rat midbrain cDNA encoding a peptide related to fish urotensin I (63% sequence identity) and to CRF (45% identity) was cloned (Vaughan et al., Nature, 1995;378(6554):287–292). The human counterpart was cloned the following year and mapped to chromosome 2; human and rat urocortin share 95% identity within the mature peptide (Donaldson et al., Endocrinology, 1996;137(5):2167–2170).
The UCN gene encodes a 124-residue precursor, and the mature hormone is residues 83 to 122 of that precursor, Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val, with a C-terminal amide (UniProt P55089). Two related genes identified in 2001 encode urocortin II (also called stresscopin-related peptide) and urocortin III (also called stresscopin), both of which bind selectively to the type 2 CRF receptor (Reyes et al., Proceedings of the National Academy of Sciences, 2001;98(5):2843–2848; Lewis et al., Proceedings of the National Academy of Sciences, 2001;98(13):7570–7575; Hsu and Hsueh, Nature Medicine, 2001;7(5):605–611). Urocortin 2 and urocortin 3 are distinct gene products from urocortin 1. No urocortin product is approved for any use in any country. Synthetic human and rat urocortin are sold as research reagents for receptor pharmacology, which is the peptide’s only market presence.
How it works
- Dual agonist at both CRF receptors. Urocortin 1 is the mammalian CRF-family ligand with high affinity for both CRF1 and CRF2 receptors; CRF itself favors CRF1, while urocortins 2 and 3 are CRF2-selective (Bale and Vale, Annual Review of Pharmacology and Toxicology, 2004;44:525–557). Synthetic human urocortin binds CRF receptor types 1, 2 alpha and 2 beta, stimulates cAMP accumulation and releases ACTH from rat pituitary cells in vitro, and the CRF-binding protein blocks that ACTH release (Donaldson et al., Endocrinology, 1996;137(5):2167–2170). Cryo-EM structures of urocortin 1 bound to CRF1R and CRF2R show the peptide as a single straight helix with its N-terminus dipped into the receptor transmembrane bundle (Ma et al., Molecular Cell, 2020;77(3):669–680.e4).
- A cardiac peptide acting through CRF2. Urocortin and CRF-R2 alpha mRNAs are expressed in all four chambers of the human heart, CRF-R1 is only weakly present and CRF mRNA is absent, so endogenous urocortin is thought to act on cardiomyocytes in an autocrine or paracrine manner through CRF2 (Kimura et al., Journal of Clinical Endocrinology and Metabolism, 2002;87(1):340–346). In primary cardiomyocytes, urocortin prevented cell death when given before simulated ischemia or at reoxygenation, acting through ERK1/2 phosphorylation, and it reduced damage in isolated rat hearts when given either before ischemia or at reperfusion (Brar et al., Journal of Biological Chemistry, 2000;275(12):8508–8514).
- Pituitary-adrenal and appetite effects in humans. In eight healthy men, a one-hour intravenous infusion of urocortin 1 roughly doubled plasma ACTH (44.6 versus 19.1 pg/mL) and cortisol (15.6 versus 7.7 µg/dL), raised atrial natriuretic peptide, and suppressed plasma ghrelin, without hemodynamic or renal effects at the dose used; the plasma half-life was 52 minutes (Davis et al., Journal of Clinical Endocrinology and Metabolism, 2004;89(3):1402–1409).
- Vasodilation and inotropy belong mainly to the CRF2-selective relatives. Intra-arterial urocortin 2 and urocortin 3 produce potent and prolonged forearm vasodilation, mediated at least partly by endothelial nitric oxide and cytochrome P450 metabolites of arachidonic acid (Venkatasubramanian et al., Journal of the American Heart Association, 2013;2(1):e004267), and intravenous urocortin 2 in healthy men raised cardiac output by up to 5.0 L/min and ejection fraction by 14.1 percentage points while lowering systemic vascular resistance (Davis et al., Journal of the American College of Cardiology, 2007;49(4):461–471).
Research status
Biomarker studies in heart failure. Plasma urocortin was elevated in 119 patients with systolic heart failure compared with 212 age- and sex-matched controls (median 50.2 versus 19.5 pmol/L in men), with the best diagnostic discrimination in early disease (Ng et al., Clinical Science, 2004;106(4):383–388), and in 299 primary-care patients with dyspnea or edema it predicted heart failure independently of N-terminal pro-BNP and clinical risk factors (Wright et al., Circulation: Heart Failure, 2009;2(5):465–471).
Urocortin 1 in experimental and human physiology. In sheep undergoing rapid left ventricular pacing, continuous urocortin 1 infusion attenuated the fall in cardiac output, prevented rises in renin, aldosterone, endothelin-1 and vasopressin, and preserved sodium excretion and creatinine clearance (Rademaker et al., American Journal of Physiology: Heart and Circulatory Physiology, 2007;293(3):H1536–H1544). The published human administration data for urocortin 1 come from the eight-man placebo-controlled crossover study from Christchurch, New Zealand, which found endocrine effects and no hemodynamic change (Davis et al., Journal of Clinical Endocrinology and Metabolism, 2004;89(3):1402–1409). Urocortin-deficient mice show heightened anxiety-like behavior and hearing impairment at the level of the inner ear (Vetter et al., Nature Genetics, 2002;31(4):363–369), and urocortin 1, like adrenomedullin, reduced established colitis in a mouse model of Crohn’s disease (Gonzalez-Rey et al., Gut, 2006;55(6):824–832); no human trial followed.
Urocortin 2 in heart failure, Christchurch program. Because urocortin 1 activates the pituitary-adrenal axis, cardiovascular development shifted to urocortin 2. In eight men with heart failure (ejection fraction below 40%, NYHA class II to III), one-hour infusions of urocortin 2 raised cardiac output by up to 2.0 L/min and ejection fraction by 14.1 percentage points while lowering mean arterial pressure by up to 19.4 mmHg, systemic vascular resistance and cardiac work, without activating vasoconstrictor hormones (Davis et al., European Heart Journal, 2007;28(21):2589–2597). The UNICORN trial then randomized 53 patients with acute decompensated heart failure to a four-hour infusion of urocortin 2 at 5 ng/kg/min or placebo as an adjunct to conventional therapy. Urocortin 2 lowered systolic blood pressure by 16 mmHg more than placebo, raised cardiac output by 2.1 L/min versus a 0.1 L/min fall (p<0.001) with a 47% reduction in calculated total peripheral resistance, and reduced B-type natriuretic peptide over 24 hours; falls in pulmonary artery and wedge pressures did not differ from placebo, and urine volume and creatinine clearance fell during the infusion before returning above baseline over the next 8 hours (Chan et al., JACC Heart Failure, 2013;1(5):433–441).
Human stresscopin (JNJ-39588146), Johnson & Johnson. The industry-sponsored program used human stresscopin acetate, a CRF2-selective member of the family, in a phase 2 study (NCT01120210) that ran from June 2010 to September 2011 at sites in Belgium, Germany, Poland and Romania. Sixty-two patients with stable heart failure and an ejection fraction of 35% or less were instrumented with a pulmonary artery catheter and randomized 3:1 to ascending one-hour infusions of 5, 15 and 30 ng/kg/min or placebo. Cardiac index rose and systemic vascular resistance fell significantly at the 15 and 30 ng/kg/min doses without change in heart rate or systolic blood pressure, but the primary analysis found no significant reduction in pulmonary capillary wedge pressure at any dose (Gheorghiade et al., European Journal of Heart Failure, 2013;15(6):679–689). The posted results list serious adverse events in 5 of 46 treated patients and 3 of 16 on placebo, and no further trial of JNJ-39588146 is registered.
Edinburgh mechanistic studies. A University of Edinburgh series registered between 2010 and 2012 (NCT01049542, NCT01096693, NCT01096706, NCT01296607 and NCT01599728) characterized urocortins 2 and 3 in healthy men and then in heart-failure patients against matched controls. Both peptides produced forearm vasodilation of similar magnitude in patients and controls, and systemic urocortin 3 raised cardiac index and lowered arterial pressure in both groups, whereas the cardiac index rise with urocortin 2 reached significance only in the heart-failure patients (Stirrat et al., British Journal of Clinical Pharmacology, 2016;82(4):974–982).
Urocortin 2 gene transfer, preclinical. A University of California, San Diego group has pursued a single intravenous injection of adeno-associated virus serotype 8 encoding urocortin 2, which increased left ventricular ejection fraction and contractile function in mice with heart failure after myocardial infarction (Lai et al., Human Gene Therapy, 2015;26(6):347–356) and normalized blood glucose and glucose disposal for months in insulin-resistant mice (Gao et al., JCI Insight, 2016;1(15):e88322). No human trial of urocortin gene transfer is registered.
GUB-UCN2, the only active clinical program. Gubra A/S of Denmark began a three-part phase 1/2a first-in-human trial of GUB-UCN2, a subcutaneous urocortin 2-based agent, with a registry start date of July 27, 2026 (NCT07702890). It plans to enroll about 188 healthy lean and obese participants and people with type 2 diabetes in single-ascending-dose, multiple-ascending-dose and up-to-16-week repeated-dose parts, alone and on top of standard-of-care obesity treatment, at a single site in Neuss, Germany, with primary completion estimated for December 2028. No human efficacy data exist.
Common dosage forms
- Research-grade synthetic peptide. Human urocortin and rat urocortin are supplied as lyophilized synthetic peptides, usually as trifluoroacetate salts, in microgram-to-milligram quantities for laboratory receptor and tissue studies.
- Investigational intravenous solutions. Urocortin 1, urocortin 2 and human stresscopin acetate were given as intravenous infusions in the clinical studies; none was ever marketed.
- No approved presentation. No injectable, oral, nasal or compounded urocortin product is approved as a drug in any country.
Key considerations
- Regulatory status. The Research Market status reflects the absence of any approved or FDA-recognized compounding product containing urocortin anywhere and of any active US-directed development program for the peptide. The only active clinical program in the family, Gubra’s GUB-UCN2 (NCT07702890), is a urocortin 2-based agent in a German phase 1/2a trial, and the intravenous heart-failure programs for urocortin 2 and stresscopin ended after small phase 2 studies completed in 2011 and published in 2013.
- Urocortin 1, 2 and 3 are different peptides. The heart-failure hemodynamic data, the UNICORN trial and the Gubra program all concern urocortin 2 or stresscopin, CRF2-selective peptides from separate genes. Urocortin 1 also activates CRF1, raises ACTH and cortisol in humans and produced no hemodynamic effect in its human infusion study, so results from the relatives cannot be transferred to it.
- Human evidence for urocortin 1 is minimal. One eight-participant crossover study is the human exposure record, and the anti-inflammatory and cardioprotective effects rest on cell, rodent and sheep experiments.
- Blood pressure and renal effects limit the class. Urocortin 2 lowered systolic blood pressure by 16 mmHg relative to placebo and transiently reduced creatinine clearance in acute heart failure, and the stresscopin study did not lower pulmonary capillary wedge pressure, so separating vasodilation from hypotension and preserving renal function remain the unresolved problems for the class.
- Naming. Urocortin, urocortin 1, urocortin I, Ucn1 and UCN all denote the same 40-residue peptide and gene. Urocortin II is also called stresscopin-related peptide, urocortin III is also called stresscopin, and JNJ-39588146 (human stresscopin acetate) and GUB-UCN2 are development codes for products based on those relatives, not for urocortin 1.